Literature DB >> 25505278

CCR2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression.

Benjamin D Clarkson1, Alec Walker2, Melissa G Harris2, Aditya Rayasam3, Matyas Sandor2, Zsuzsanna Fabry4.   

Abstract

Dendritic cells (DCs)--although absent from the healthy CNS parenchyma--rapidly accumulate within brain and spinal cord tissue during neuroinflammation associated with experimental autoimmune encephalomyelitis (EAE; a mouse model of multiple sclerosis). Yet, although DCs have been appreciated for their role in initiating adaptive immune responses in peripheral lymphoid organ tissues, how DCs infiltrate the CNS and contribute to ongoing neuroinflammation in situ is poorly understood. In this study, we report the following: 1) CD11c(+) bone marrow-derived DCs and CNS-infiltrating DCs express chemokine receptor CCR2; 2) compared with CCR2(+/+) cells, adoptively transferred CCR2(-/-) bone marrow-derived DCs or DC precursors do not accumulate in the CNS during EAE, despite abundance in blood; 3) CCR2(-/-) DCs show less accumulation in the inflamed CNS in mixed bone marrow chimeras, when compared with CCR2(+/+) DCs; and 4) ablation of CCR2(+/+) DCs during EAE clinical onset delays progression and attenuates cytokine production by infiltrating T cells. Whereas the role of CCR2 in monocyte migration into the CNS has been implicated previously, the role of CCR2 in DC infiltration into the CNS has never been directly addressed. Our data suggest that CCR2-dependent DC recruitment to the CNS during ongoing neuroinflammation plays a crucial role in effector T cell cytokine production and disease progression, and signify that CNS-DCs and circulating DC precursors might be key therapeutic targets for suppressing ongoing neuroinflammation in CNS autoimmune diseases.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505278      PMCID: PMC4362728          DOI: 10.4049/jimmunol.1401320

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

Authors:  Melanie Greter; Frank L Heppner; Maria P Lemos; Bernhard M Odermatt; Norbert Goebels; Terri Laufer; Randolph J Noelle; Burkhard Becher
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

2.  Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.

Authors:  Eileen J McMahon; Samantha L Bailey; Carol Vanderlugt Castenada; Hanspeter Waldner; Stephen D Miller
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

Review 3.  Statistical analysis of data from studies on experimental autoimmune encephalomyelitis.

Authors:  Kandace K Fleming; James A Bovaird; Michael C Mosier; Mitchell R Emerson; Steven M LeVine; Janet G Marquis
Journal:  J Neuroimmunol       Date:  2005-09-29       Impact factor: 3.478

4.  Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases.

Authors:  Alla L Zozulya; Emily Reinke; Dana C Baiu; Jozsef Karman; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

5.  Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis.

Authors:  A E Juedes; N H Ruddle
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

6.  Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells.

Authors:  Andres Gottfried-Blackmore; Ulrike W Kaunzner; Juliana Idoyaga; Jennifer C Felger; Bruce S McEwen; Karen Bulloch
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

7.  Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS.

Authors:  Alla L Zozulya; Sonja Ortler; JangEun Lee; Christian Weidenfeller; Matyas Sandor; Heinz Wiendl; Zsuzsanna Fabry
Journal:  J Neurosci       Date:  2009-01-07       Impact factor: 6.167

8.  Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

Authors:  Mitsugu Fujita; Xinmei Zhu; Ryo Ueda; Kotaro Sasaki; Gary Kohanbash; Edward R Kastenhuber; Heather A McDonald; Gregory A Gibson; Simon C Watkins; Ravikumar Muthuswamy; Pawel Kalinski; Hideho Okada
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

9.  Blood-brain barrier disruption in CCL2 transgenic mice during pertussis toxin-induced brain inflammation.

Authors:  Angela E Schellenberg; Richard Buist; Marc R Del Bigio; Henrik Toft-Hansen; Reza Khorooshi; Trevor Owens; James Peeling
Journal:  Fluids Barriers CNS       Date:  2012-04-30

10.  MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8⁺ T cells.

Authors:  Qingyong Ji; Luca Castelli; Joan M Goverman
Journal:  Nat Immunol       Date:  2013-01-06       Impact factor: 25.606

View more
  28 in total

1.  A Novel In Vitro Mouse Model to Study Mycobacterium tuberculosis Dissemination Across Brain Vessels: A Combination Granuloma and Blood-Brain Barrier Mouse Model.

Authors:  Fruzsina R Walter; Trey E Gilpin; Melinda Herbath; Maria A Deli; Matyas Sandor; Zsuzsanna Fabry
Journal:  Curr Protoc Immunol       Date:  2020-09

Review 2.  Dendritic cell migration in health and disease.

Authors:  Tim Worbs; Swantje I Hammerschmidt; Reinhold Förster
Journal:  Nat Rev Immunol       Date:  2016-11-28       Impact factor: 53.106

Review 3.  Infectious immunity in the central nervous system and brain function.

Authors:  Robyn S Klein; Charise Garber; Nicole Howard
Journal:  Nat Immunol       Date:  2017-01-16       Impact factor: 25.606

4.  Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Authors:  Victor A Gall; Anne V Philips; Na Qiao; Karen Clise-Dwyer; Alexander A Perakis; Mao Zhang; Guy T Clifton; Pariya Sukhumalchandra; Qing Ma; Sangeetha M Reddy; Dihua Yu; Jeffrey J Molldrem; George E Peoples; Gheath Alatrash; Elizabeth A Mittendorf
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

Review 5.  Effective effectors: How T cells access and infiltrate the central nervous system.

Authors:  Kendra L Congdon; Luis A Sanchez-Perez; John H Sampson
Journal:  Pharmacol Ther       Date:  2018-12-14       Impact factor: 12.310

Review 6.  Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.

Authors:  Sudhir Kumar Yadav; Devika Soin; Kouichi Ito; Suhayl Dhib-Jalbut
Journal:  J Mol Med (Berl)       Date:  2019-02-28       Impact factor: 4.599

7.  Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis.

Authors:  Kazuyoshi Ishigaki; Yuta Kochi; Akari Suzuki; Yumi Tsuchida; Haruka Tsuchiya; Shuji Sumitomo; Kensuke Yamaguchi; Yasuo Nagafuchi; Shinichiro Nakachi; Rika Kato; Keiichi Sakurai; Hirofumi Shoda; Katsunori Ikari; Atsuo Taniguchi; Hisashi Yamanaka; Fuyuki Miya; Tatsuhiko Tsunoda; Yukinori Okada; Yukihide Momozawa; Yoichiro Kamatani; Ryo Yamada; Michiaki Kubo; Keishi Fujio; Kazuhiko Yamamoto
Journal:  Nat Genet       Date:  2017-05-29       Impact factor: 38.330

8.  Tubular GM-CSF Promotes Late MCP-1/CCR2-Mediated Fibrosis and Inflammation after Ischemia/Reperfusion Injury.

Authors:  Leyuan Xu; Diana Sharkey; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2019-07-17       Impact factor: 10.121

9.  Conditional Silencing of H-2Db Class I Molecule Expression Modulates the Protective and Pathogenic Kinetics of Virus-Antigen-Specific CD8 T Cell Responses during Theiler's Virus Infection.

Authors:  Zachariah P Tritz; Robin C Orozco; Courtney S Malo; Katayoun Ayasoufi; Cori E Fain; Roman H Khadka; Emma N Goddery; Lila T Yokanovich; Megan L Settell; Michael J Hansen; Fang Jin; Kevin D Pavelko; Larry R Pease; Aaron J Johnson
Journal:  J Immunol       Date:  2020-07-31       Impact factor: 5.422

10.  Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.

Authors:  Ryan C Winger; Christopher T Harp; Ming-Yi Chiang; David P Sullivan; Richard L Watson; Evan W Weber; Joseph R Podojil; Stephen D Miller; William A Muller
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.